Bergen, Norway, 8 September 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, will present study updates from its Phase II clinical development programme with bemcentinib (BGB324), a first-in-class highly selective oral AXL inhibitor, in non-small cell lung cancer (NSCLC) at the 2019 World Conference … Read more
Bergen, Norway, 3 September 2019 – Reference is made to the stock exchange notice published by BerGenBio ASA (the “Company”) (OSE: BGBIO) on 28 August 2019 where the Company announced that the board of directors of the Company had resolved to increase the Company’s share capital in connection with the exercise options pursuant to the … Read more
Bergen, Norway, 2 September 2019. BerGenBio ASA (the”Company”) (OSE: BGBIO). Reference is made to the stock exchange notice dated 28 August 2019 and primary insiders exercise of share options which expire in 2019. Primary Insider Richard Godfrey (CEO) exercised 225,000 options equal to 225,000 shares. To cover costs related to the exercise, Richard Godfrey transferred … Read more
Bergen, Norway, 28 August 2019. The Board of Directors of BerGenBio ASA (the “Company”) (OSE: BGBIO) have, to fulfil the Company’s obligations under the share option agreements and in accordance with the authorisation granted by the general meeting on 13 March 2019, resolved to increase the Company’s share capital by NOK 54,000 by issuance of … Read more
Acute Myeloid Leukaemia (AML): Preliminary Phase II clinical shows promising efficacy for bemcentinib in combo with low-intensity chemo in elderly AML patients unfit for intensive therapy Non small cell lung cancer (NSCLC): Phase II clinical data continues to show promising clinical activity and improved overall survival, particularly in patients with AXL positive tumours including those … Read more
Acute Myeloid Leukaemia (AML): Preliminary Phase II clinical shows promising efficacy for bemcentinib in combo with low-intensity chemo in elderly AML patients unfit for intensive therapy Non small cell lung cancer (NSCLC): Phase II clinical data continues to show promising clinical activity and improved overall survival, particularly in patients with AXL positive tumours including those … Read more
Acute Myeloid Leukaemia (AML): Preliminary Phase II clinical shows promising efficacy for bemcentinib in combo with low-intensity chemo in elderly AML patients unfit for intensive therapy Non small cell lung cancer (NSCLC): Phase II clinical data continues to show promising clinical activity and improved overall survival, particularly in patients with AXL positive tumours including those … Read more
Bergen, Norway, 8 August 2019 – BerGenBio ASA (OSE:BGBIO), will announce its results for the second quarter on Monday, 19 August 2019. A presentation by BerGenBio’s senior management team will take place at 10am CEST at: Carnegie AS Fjordalleen 16, 5. floor,Aker Brygge,Oslo The presentation will webcast live and the link will be available at www.bergenbio.com in the … Read more
Bergen, Norway, 1 July 2019 – Reference is made to the stock exchange notice published by BerGenBio ASA (the “Company”) (OSE: BGBIO) on 28 June 2019 where the Company announced that the board of directors of the Company had resolved to increase the Company’s share capital in connection with the exercise options pursuant to the … Read more
Bergen, Norway, 28 June 2019: BerGenBio ASA (the “Company”) (OSE: BGBIO) today announces that in order to to fulfil the Company’s obligations under its option scheme, the Board of Directors has resolved to increase the Company’s share capital by NOK 9,000 by issuance of 90,000 new shares. The new shares have been issued to an … Read more
soug@oncoinvent.com
Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.
Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997
mansson@oncoinvent.com
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.